Assessing ADMA Biologics: Insights From 4 Financial Analysts
Assessing ADMA Biologics: Insights From 4 Financial Analysts
評估adma biologics：來自4個財務分析師的見解
Exploring Analyst Ratings: An In...Ratings for ADMA Biologics (NASDAQ:ADMA) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在過去三個月中，有4位分析師提供了ADMA Biologics（納斯達克股票代碼：ADMA）的評級，顯示了看漲和看跌的觀點。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您將找到他們最近的評級摘要，揭示了過去30天中情緒的變化，並將其與前幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for ADMA Biologics, presenting an average target of $16.75, a high estimate of $20.00, and a low estimate of $14.00. Witnessing a positive shift, the current average has risen by 42.55% from the previous average price target of $11.75.
在評估12個月目標股價時，分析師公佈了對ADMA Biologics的見解，將平均目標價定爲16.75美元，最高估計爲20.00美元，低估值爲14.00美元。當前的平均價格從之前的平均目標價11.75美元上漲了42.55％，這是一個積極的轉變。
Exploring Analyst Ratings: An In...
探索分析師...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間